• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Metasyn joins forces with Daiichi

Article

Contrast developer Metasyn has signed a $12 million agreementwith Daiichi Radioisotope Laboratories of Tokyo for Japanese developmentand marketing of MS-325, Metasyn's vascular MRI contrast agent.Under the agreement, Metasyn will receive $12 million in

Contrast developer Metasyn has signed a $12 million agreement

with Daiichi Radioisotope Laboratories of Tokyo for Japanese development

and marketing of MS-325, Metasyn's vascular MRI contrast agent.

Under the agreement, Metasyn will receive $12 million in license

fees, milestone payments, and an equity investment, in addition

to royalties on sales of the product. Daiichi will be responsible

for clinical development, registration, and commercialization

of MS-325 in Japan. Metasyn, of Cambridge, MA, will manufacture

MS-325 for Daiichi and will retain rights to the product outside

Japan. Metasyn expects to begin clinical trials of the agent in

the U.S. this year.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.